U.S. markets closed

Enveric Biosciences, Inc. (ENVB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2126-0.0017 (-0.79%)
At close: 04:00PM EDT
0.2130 +0.00 (+0.19%)
After hours: 07:58PM EDT

Enveric Biosciences, Inc.

4851 Tamiami Trail North
Suite 200
Naples, FL 34103
United States
239 302 1707

Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Mr. David Ian JohnsonExec. Chairman418.75kN/A1958
Dr. Joseph Edward Tucker Ph.D.CEO & Director474.82kN/A1969
Mr. Avani V. KanubaddiPres & COO447.07kN/A1973
Mr. Carter J. Ward CPA, CSCPChief Financial OfficerN/AN/A1964
Dr. Peter J. Facchini Ph.D.Chief Innovation Officer303.52kN/A1964
Dr. Ibrahim Dagher M.D.Chief Medical OfficerN/AN/A1969
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Corporate Governance

Enveric Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.